$FEMY News

Femasys Announces CE Mark Approval For FemHSG Catheter, Further Expanding Its Portfolio In Europe Through Commercial Partners

Femasys Announces First Revenue-Generating Commercial Use Of Its Fertility Portfolio In An OBGYN Setting, Led By FemaSeed As A First-Line Infertility Treatment

Femasys Collaborates With AMI Technologies To Roll Out, Commercialize Fertility Portfolio In Israel

Femasys Appoints John Canning COO

Femasys Q4 EPS $(0.06) Beats $(0.12) Estimate, Sales $813.387K Miss $1.450M Estimate

Femasys Initiates Participant Enrollment In FINALE Pivotal Clinical Study Of FemBloc

Lake Street Initiates Coverage On Femasys with Buy Rating, Announces Price Target of $1.5

Femasys' FemBloc Permanent Birth Control System Gets Certification Under Medical Device Single Audit Program

Femasys Secures American Medical Association CPT Editorial Panel Approval For Category III CPT Code Covering Use Of FemaSeed For Intratubal Insemination

Femasys Partners With OR Consulting Over Commercial Rollout Of Product Portfolio In Switzerland

Femasys shares are trading higher after the company announced that it has been granted 180-day extension by Nasdaq to regain compliance with minimum bid price requirement.

Femasys shares are trading higher after the company announced that it has been granted 180-day extension by Nasdaq to regain compliance with minimum bid price requirement.

Femasys Gets Nasdaq's 180-Day Extension Through July 13 To Regain Compliance

Femasys Partners With Refuah Health Center To Offer FemaSeed As First Step In Infertility Treatment Process

Femasys Files Prospectus For Offer, Sale Of Shares In $9.8M Common Stock Offering

Femasys shares are trading higher after the company announced that it has received 510(k) clearance from the FDA for its FemVue Controlled device.

Femasys Receives 510(k) Clearance From FDA For FemVue Controlled Device, Diagnostic Solution For Controlled Contrast Delivery To Evaluate Fallopian Tube Status

Femasys shares are trading higher after Laidlaw initiated coverage on the stock with a Buy rating and announced a $6.50 price target.

Laidlaw & Co. Initiates Coverage On Femasys with Buy Rating, Announces Price Target of $6.5

Femasys Q3 EPS $(0.10) Beats $(0.12) Estimate, Sales $729.394K Miss $1.450M Estimate